• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Combination adjuvant therapy for esophageal carcinoma

Research Project

Project/Area Number 60480315
Research Category

Grant-in-Aid for General Scientific Research (B)

Allocation TypeSingle-year Grants
Research Field Thoracic surgery
Research InstitutionToyama Medical & Pharmaceutical University

Principal Investigator

FUJIMAKI Masao  Toyama Medical & Pharmaceutical University, 医学部, 教授 (50018355)

Co-Investigator(Kenkyū-buntansha) OTAGIRI Haruyo  Toyama Medical & Pharmaceutical University, 医学部, 助手 (40160882)
MUNAKATA Shuji  Toyama Medical & Pharmaceutical University, 医学部, 助手 (00157728)
KARAKI Yoshiaki  Toyama Medical & Pharmaceutical University, 附属病院, 講師 (20143852)
Project Period (FY) 1985 – 1986
Project Status Completed (Fiscal Year 1986)
Budget Amount *help
¥6,300,000 (Direct Cost: ¥6,300,000)
Fiscal Year 1986: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1985: ¥5,300,000 (Direct Cost: ¥5,300,000)
Keywordshuman esophageal carcinoma cell line / transplantable human esophageal carcinoma into nude mouse / experimental esophageal carcinoma / chemotherapy / hyperthermia / combination hyperchermockcmotherapy
Research Abstract

Various kinds of adjuvant therapies have been employed for the treatment of esophageal carcinoma.Among of them,hyperthermia has recently become a useful therapeutic method in treating esophageal carcinomas and has been spread clinically into many facilities in Japan. However, the basic studies of hyperthermia are not sufficient to allow application of this method to all clinical cases. In the present study, the cell biological effects of hyperthermia and thermochemotherapy on cultured human esophageal cancer cells were investigated. We have already established three cell lines designated SGF-3, -4 and -5 derived from three different human esophageal carcinomas. These cell lines employed in the present study have been maintained in RPMI-1640 and HAM F-12(1:1) containing 10% pseudofetal bovine serum and incubated at 37゜C in a humidified atomosphere 5% <CO_2> in air. Cells were treated with hyperthermia in the temperature gradient incubator (TN-206), in which the temperature and humidiy in the chambers were disigned to be exactly adjusted. Drugs used were adriamycin (ADR) bleomycin,cisplatin (CDDP), 5-fluorouracil and mitomycin C (MMC). Cell growth was determined by viable cell count stained by 0.2% nigrosin dye. Proliferation of SGF-3 was inhibited at more than 40゜C, SGF-4 at more than 41゜C and SGF-5 at more than 42゜C. When cells were exposed to a drug at 37゜C, three cell lines showed the different cytotoxic effects of the drug, respectively. Effective drugs in combination with hyperthermia were CDDP and ADR on SGF-3, CDDP on SGF-4 and ADR and MMC on SGF-5.
Furthermore, administration of 5FU in advance, which is said to have an action of accumulating cancer cells in S-Phase,hyperthermia with simultaneous application of various kind of drugs showed more effective inhibition of proliferation.

Report

(1 results)
  • 1986 Final Research Report Summary
  • Research Products

    (4 results)

All Other

All Publications (4 results)

  • [Publications] Masaru Sawataishi: Jop.J.Clinical Electron Microscopy. 18. 375-387 (1985)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1986 Final Research Report Summary
  • [Publications] Takashi Shinbo: In Vitro.

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1986 Final Research Report Summary
  • [Publications] Masaru Sawataishi: "Effects of mitomycin C on the nucleolar ultrastructure of a human esophageal cancer cell line" Jap. J. Clinical Electron Microscopy. 18. 375-387 (1985)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1986 Final Research Report Summary
  • [Publications] Takashi Shinbo: "The characteristics on two cell lines in vitro derived from human esophageal carcinomas" In Vitro.

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1986 Final Research Report Summary

URL: 

Published: 1987-03-31   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi